Casdin Capital, LLC Beam Therapeutics Inc. Transaction History
Casdin Capital, LLC
- $1.16 Billion
- Q2 2024
A detailed history of Casdin Capital, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 675,000 shares of BEAM stock, worth $16 Million. This represents 1.36% of its overall portfolio holdings.
Number of Shares
675,000
Previous 675,000
-0.0%
Holding current value
$16 Million
Previous $15.8 Million
-0.0%
% of portfolio
1.36%
Previous 1.37%
Shares
7 transactions
Others Institutions Holding BEAM
# of Institutions
229Shares Held
71.7MCall Options Held
283KPut Options Held
233K-
Farallon Capital Management LLC San Francisco, CA7.91MShares$187 Million0.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$187 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$180 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.63MShares$180 Million1.63% of portfolio
-
Arch Venture Management, LLC Chicago, IL5.44MShares$129 Million74.72% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.66B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...